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Abstract: The purpose of this work was to investigate if P-glycoprotein (Pgp) efflux pump activity 
could be inhibited in the sub-bronchial epithelial cell line, Calu-3, by glucocorticosteroids and β-
ligands.  The Pgp modulation efficiency of each compound was determined by its ability to 
increase the accumulation of the Pgp substrate rhodamine 123 (Rh123) accumulation in these 
cells. Pgp inhibition was observed at ≥ 100 µM steroids and β-ligand.  The modulation 
effectiveness of the β-ligands increased with increasing hydrophobicity (log Poctanol/aqueous) 
whereas an obvious correlation was not obtained with the complete set of steroids tested.  
Steroidal Pgp substrates did not affect Rh123 accumulation (e.g., aldosterone, dexamethasone, 
11β, 17α, 21-OH progesterone).   In contrast, two hydrophobic non P-gp steroidal substrates 
(testosterone and progesterone) displayed different effects on Rh123 accumulation, with 
progesterone being the more potent modulator.  The most hydrophobic β-ligand, propranolol, 
a known Pgp substrate, gave the largest increase in Rh123 accumulation in this therapeutic 
class. The β-ligand modulation efficiency could also be correlated to Pgp structural recognition 
elements such as hydrogen bonding potential, the presence of a basic nitrogen and planar 
aromatic ring. No effect on Rh123 accumulation was observed with the formulation additives 
tested (ethanol, glycerol and palmitoyl carnitine) at concentrations previously reported to be 
non-toxic to Calu-3 cells. 
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1.  INTRODUCTION 
Inhaled glucocorticosteroids are used in asthma therapy for their anti-inflammatory effects (Smith and 
Bernstein, 1996).  A number of studies have shown that glucocorticosteroids interact with Pgp to either 
bind to, be transported by, or affect the expression and action of this efflux pump.  The high levels and 
wide tissue distribution of Pgp expression in the adrenal gland, the site of glucocorticosteroid synthesis, 
provided an early indication that Pgp may play a role in steroid transport (Fojo et al., 1987; Thiebaut et 
al., 1987).  Consistent with these observations, it was later shown that Pgp transports aldosterone, 
cortisol and dexamethasone, however the more hydrophobic steroids, β-estradiol, progesterone and 
testosterone are not substrates for Pgp efflux  (Ueda et al., 1992; Ueda et al., 1994).  The incorporation 
of hydroxyl groups on the steroid ring system at carbons 11, 16, 17 and 21, impart varying degrees of 
decreased hydrophobicity, and has been shown to determine steroid transport by Pgp (Gruol et al., 
1994).  A relationship between increased steroid hydrophobicity and increased retention of the Pgp 
substrate vinblastine has also been demonstrated (Yang et al., 1989).  In similar studies, Naito et al. 
(1989) reported inhibition of binding of another Pgp substrate, vincristine, by several steroid hormones 
including β-estradiol, cortisone, corticosterone, testosterone and progesterone.  Finally, steroids have 
also been shown to regulate Pgp expression.  Estrogen and progesterone have been reported to induce 
murine mdr1 and Pgp expression in the uterus during pregnancy (Arceci et al., 1990). On the other hand, 
dexamethasone modulation of Pgp expression appears to be tissue specific (Sérée et al., 1998; Demeule 
et al., 1999). 
 
In contrast, there are few reports in the literature on the interactions of β-ligands with Pgp. The 
cardioselective β-blockers acebutolol, celiprolol and talinolol, have been shown to exhibit Pgp-mediated 
secretion in intestinal Caco-2 cells (Karlsson et al., 1993; Terao et al., 1996; Hilgendorf et al., 2000). 
Propranolol uptake was reported to be increased by several Pgp ligands including cyclosporin A, 
progesterone and Rh123, in conjuctival epithelium (Yang et al., 2000).  More recently, Pgp was shown to 
restrict the transport of bunitrolol across the blood-brain barrier (Matsuzaki et al., 1999).   Inhaled β2-
adrenergic agonists such as albuterol and terbutaline provide quick bronchodilatory relief in asthma 
patients (Smith and Bernstein, 1996).  There are no reports, however, on the involvement of Pgp in the 
pulmonary absorption of anti-asthmatic agents. 
 
The lung is known to express low levels of Pgp relative to other tissues (Fojo et al., 1987).  In particular, 
Pgp expression has been demonstrated in normal human bronchial epithelium and expression levels in 
normal lung have been reported to exceed those in cancerous tissue (Pavelic et al., 1993; Abe et al., 
1994).  Although the exact role of Pgp in the lung is unknown, Pgp may function to protect the lung from 
toxic levels of xenobiotics, as has been proposed for other tissues (Thiebaut et al., 1987). We have 
recently demonstrated functional Pgp activity in Calu-3 cells, a model of the human sub-bronchial 
epithelium (Hamilton et al., 2001a).  If Pgp does indeed play a role in restricting the absorption of 
potential substrates in the lung, then circumvention of this pathway may improve the delivery of 
pulmonary therapeutics.  With this is mind, we sought to investigate if Pgp activity in Calu-3 cells could 
be inhibited with a number of steroids and β-ligands varying in chemical structure, lipophilicity and their 
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intrinsic ability to be transported by Pgp (Figures 1, 2, 3). Although Rh123 has been shown to be a 
substrate for both Pgp and MRP1 (Twentyman et al., 1994; Versantvoort et al., 1996), we have shown 
predominant Pgp activity in Calu-3 cells (Hamilton et al., 2001b) using this marker compound. 
 
2.  MATERIALS AND METHODS 
2.1 Materials 
Calu-3 cells were obtained from the American Type Culture Collection (Rockville, MD).  Cell culture 
medium and buffer solutions were obtained from Gibco BRL (Gaithersburg, MD). Accumulation studies 
were all performed in pH 7.4 standard phosphate buffered saline (PBS) supplemented with 0.63 mM 
CaCl2, 0.74 mM MgSO4, 5.3 mM glucose and 0.1 mM ascorbic acid (PBSA).  Culture flasks (150 cm
2 
growth area), 12 well cluster dishes (1.1 cm2 growth area) and polycarbonate Transwells (0.4 µM pore 
size) were obtained from Corning Costar (Cambridge, MA). Aldosterone, beclomethasone, budenoside, 
cylcosporine A, dexamethasone, flunisolide, rhodamine 123, testosterone, triamcinolone, progesterone, 
11α-OH progesterone, 11β-OH progesterone, 21-OH progesterone, 11β, 11β, 21-OH progesterone, 17α, 
21-OH progesterone and 11β, 17α, 21-OH progesterone were obtained from Sigma (St. Louis, MO). 17α-
OH progesterone was obtained from ICN Biomedicals (Aurora, OH).  The β-ligands acebutolol, albuterol 
hemisulfate, metoprolol, nadolol, propanolol and timolol were also obtained from Sigma.  Albuterol 
sulfate was a gift from Boehringer Ingelheim Inc. (Ridgefield, CT).  All other reagents were from Sigma. 
Cyclosporin A (CsA) was first dissolved in methanol (Fisher Scientific, Fair Lawn, NJ) to 5 mM then 
aliquots diluted in PBS to give a 5 µM final working concentration. 
 
2.2 Cell culture 
All cell lines were maintained in a 95% humidified/10%CO2 atmosphere at 37°C.  Calu-3 cells were used 
between passages 19 and 40.  The cells were grown in 150 cm2 flasks and maintained in a 1:1 mixture of 
Ham’s F12:DMEM containing 10% fetal bovine serum (FBS),  100 µg/ml penicillin G and 100 µg/ml 
streptomycin sulfate.  When the cells reached 90% confluency (approximately 4-5 days) they were 
subcultured at a 1:2 split ratio using 0.25% trypsin/0.1% EDTA. Caco-2 cells were cultured in DMEM 
containing 10% FBS, 1% non-essential amino acids, 2 mM glutamine, 100 µg/ml penicillin G and 100 
µg/ml streptomycin sulfate. A549 cells were maintained in Ham’s F-12 medium supplemented with 10% 
FBS, 100 µg/ml penicillin G and 100 µg/ml streptomycin sulfate.  
 
 
2.3 Rh123 accumulation assay 
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Cells were seeded onto 12 well cluster dishes at a density of 5 x 105 cells/cm2 (1 ml per well). 
The culture medium was changed every other day after seeding until a confluent monolayer 
was formed (by day 4) as determined by light microscopy.  Experiments were performed in 
PBSA. All experiments were performed with gentle agitation (~ 30 rpm) at 37°C.  The growth 
medium was first aspirated off and then the cells were rinsed three times with pre-warmed 
(37°C) PBSA. The monolayers were then equilibrated either in 1 ml PBSA for 1 hour at 37°C for 
control experiments or equilibrated for 30 minutes in PBSA alone, followed by another 30 
minute pre-incubation with the steroid, β-ligand or excipient.  CsA (5 µM) was used as the 
positive control. Rh123 accumulation was then performed for 2 hours with or without 
modulator present. At the end of the experiment, the drug solution was removed by aspiration 
and the monolayers were immediately rinsed three times with ice-cold PBSA.   Each monolayer 
was solubilized for 30 minutes (37°C) with 1 ml of lysing solution (0.5% v/v Triton X-100 in 0.2 N 
NaOH).  For cells grown in 96 well format (0.32 cm2 total surface area), the following 
adjustments were made to the protocol outlined above.  Cells were plated at the same density 
with 100 µl per well, and a confluent monolayer was formed by day 2.  Volumes for pre-
incubations and incubations were 100 µl and cells were lysed in 200 µl volume.  For both 
plating conditions, cell lysates were assayed using a microplate fluorescence reader (Bio-Tek 
Instruments, Winooski, VT) at excitation/emission wavelengths of 485 nm/520 nm, then 
quantified against standard curves of Rh123 in lysing solution. The fluorescence of the cell 
lysates was corrected for autofluorescence of untreated cells. The protein content of each 
monolayer was then determined using the BCA protein assay reagent kit.  Results were 
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expressed as total Rh123 accumulation per µg cellular protein or a percentage of Rh123 uptake 
compared to control wells. 
 
2.4 Software analysis 
All experiments were performed at least in quadruplicate.  Data are presented as mean ± standard 
deviation.  Statistical significance and linear regression analyses were  performed using the unpaired 
student’s t-test (Sigma Plot version 4.01) determined at the 95% confidence level.  Estimated log P 
values (log Kow) were retrieved from the online-interactive Syracuse Research Corporation KowWin 
program (http://esc.syrres.com/interkow/kowdemo.htm). 
 
3.  RESULTS 
3.1 Effect of progesterone, dexamethasone and their analogs 
For most agents tested, an increase in Rh123 accumulation was not observed until 100 µM 
concentration.  Figure 4 shows the correlation between estimated log P (log Kow) and % Rh123 of 
control values.  Log Kow values were plotted rather than log P values due to incomplete availability of 
measured log P values in the literature.  It should be noted that the overall data trend was not affected 
by plotting log Kow rather than log P.  Modulation efficiency appears to fall into three distinct 
categories, relative to log Kow;  log Kow of 3.67, log Kow between 3.08 and 3.27 and log Kow less than 
2.18.  No modulation was observed with steroids that are highly transported by Pgp (aldosterone, 
dexamethasone, 11β, 17α, 21-OH progesterone).   On the other hand, testosterone and progesterone, 
compounds that do not display Pgp transporting activity, increased Rh123 accumulation approximately 
1.7 and 4.0 fold, respectively.    Progesterone analogs with varying degrees of hydroxyl substitution 
showed varying degrees of modulation. The inhalation steroids also varied in their Pgp inhibitory effects, 
with triamcinolone being the least effective of this series.  A summary of all the steroids tested along 
with their corresponding log P and log Kow values relative to modulation efficiency is shown in Table 1.  
 
3.2 Effect of β-ligands 
A concentration dependent effect was also observed (1 µM to 1 mM) for all the compounds tested, with 
higher concentrations showing greater inhibitory effects on Rh123 efflux.  Representative dose – 
response curves are shown in Figure 5 for the β-ligands nadolol and metoprolol. Figure 6 shows the 
correlation between log P and Rh123 accumulation (as % control) for the seven β-ligands tested (100 
µM).   The data for the 100 µM treatment are summarized in Table 2 using a ranking system similar to 
that provided for the steroids in Table 1.  A clear trend was observed between increasing log P and the 
ability to inhibit Rh123 efflux.  However, the Pgp substrate propranolol gave the largest increase in 
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Rh123 accumulation. Cellular toxicity was observed with this agent at > 100 µM, which was manifested 
as a decrease in Rh123 and detachment of the cell monolayer from the plastic support during the 
incubation period.  Metoprolol, acebutolol and timolol showed similar inhibitory effects relative to each 
other.  No modulation was observed with those compounds exhibiting log P values < 1.  No effect on 
Rh123 accumulation was observed with the bronchodilator, albuterol. 
 
3.3 Effect of ethanol, glycerol and palmitoyl carnitine 
The effects of various formulation additives on Pgp activity were investigated (data not shown).  No 
effect on Rh123 accumulation was observed with 0.1% (v/v) and 1.0% (v/v) glycerol.  Similarly, 0.05% 
(v/v) and 0.5% (v/v) DMSO; 0.08% EtOH; 0.08% (v/v) and 0.82% MeOH solvent controls did not affect 
Rh123 accumulation.  The permeation enhancer palmitoyl carnitine did not affect Rh123 accumulation 
at 10 µM. The 100 µM treatment, however, also resulted in cellular toxicity similar to those observed 
with high concentrations of propranolol. 
 
4.  DISCUSSION 
We show here that steroids and β-ligands vary in their ability to modulate Pgp in Calu-3 cells. 
Whereas both therapeutic classes inhibit Rh123 efflux with increasing hydrophobicity, steroidal 
Pgp substrates are non-modulating while the β-ligand substrate, propranolol was the most 
effective inhibitor in its class.  Although propranolol and progesterone exhibit similar log P 
values (3.21 and 3.26, respectively), progesterone increased Rh123 accumulation 4-fold, while 
propranolol produced a 2-fold increase in accumulation.  Thus, progesterone appears to be a 
more potent inhibitor of Pgp efflux at equimolar concentrations using the model substrate, 
Rh123. 
 
Certain structural elements have previously been identified as essential for recognition by Pgp. 
These include a basic nitrogen atom, and the presence of at least one planar aromatic ring 
(Pearce et al., 1989).  The β-ligands tested are all weak bases, and therefore positively charged 
at physiological pH (pKa ≈ 9.5).  This additional feature would make these compounds ideal 
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candidates for interaction with Pgp.  It has also been suggested that substrate binding to Pgp is 
approximately proportional to the number and strength of hydrogen bonds formed between 
the Pgp ligand and receptor protein (Seelig, 1998).  Furthermore, it has been shown that 
carbonyl groups and ether linkages are prevalent in Pgp substrates (Seelig, 1998).  Propranolol 
possesses an ether linkage coupled to a fused aromatic ring system.  This unique structural 
combination is absent in any of the other β-ligands tested, and may account for the enhanced 
inhibitory effect of this compound.   
 
On the other hand, the steroids tested represent un-ionizable compounds, and lack a basic 
nitrogen atom, in addition to aromaticity.  Their ability to be recognized by Pgp therefore may 
be a function of relative hydrophobicity, rather than the structural requirements outlined 
above (Ueda et al., 1997).  The ability of these steroids to modulate Pgp also appears to follow 
the same pattern observed for substrate recognition.  The highly transported Pgp substrates 
aldosterone, dexamethasone and the tri-hydroxyl substituted progesterone analog, did not 
modulate Rh123 efflux.  The moderately transported progesterone analogs (mono- and di-
hydroxyl substituted) gave intermediate effects, increasing Rh123 accumulation 1.4 to 2.1 fold.  
Interestingly, the non-transported steroid progesterone was a greater inhibitor of Rh123 efflux 
than CsA (% Rh123 control = 307.1 ± 18.4, 5 µM CsA; 405.0 ± 38.5, 100 µM progesterone).  
Testosterone differs from progesterone by possessing a hydroxyl group on the position-20 
carbon, however,  this steroid did affect Pgp activity (1.7-fold). Thus, hydroxylation at carbon 20 
may be important for steroidal modulation of this efflux pump transporter.   
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Of the inhalation steroids tested, budenoside was the most potent modulator, second only to 
CsA in Pgp inhibitory effect.  The closely related steroid, flunisolide, displayed intermediate 
effects on Pgp activity.  These differences can most likely be attributed to chemical structure 
(Figure 2).  The only other fluorinated steroid tested was triamcinolone, for which no 
modulation of Pgp activity was observed despite possessing two hydroxyl groups on carbons 16 
and 17. 
 
Finally, we investigated the ability of various formulation additives to affect Pgp activity.  Foster 
et al. (2001) reported that a concentration of glycerol of up to 1% (v/v) did not affect ion 
movement across Calu-3 monolayers as assessed by measurement of transepithelial electrical 
resistance (TEER) values.  We did not observe any changes in Rh123 accumulation at 0.1 % and 
1% (v/v) of this cosolvent.  DMSO, ethanol and methanol were tested in the studies reported 
here at the given concentrations as vehicle controls; none of these agents caused an apparent 
effect on Pgp activity.  The permeation enhancer, palmitoyl carnitine did, however, prove to be 
cytotoxic at 100 µM.  This result is consistent with previous studies reporting tissue irritancy of 
this formulation agent. 
 
5. CONCLUSIONS 
We have shown that steroids and β-ligands can be used to modulate Pgp activity in vitro, 
however, both classes of agents display unique physico-chemical and structural features that 
may explain the differences observed in modulation efficiency.  It should be noted, however, 
that a more detailed structure activity relationship would be needed to confirm the data and 
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hypotheses presented here.  Of the 100 compounds initially detailed by Seelig et al. (1998) for 
Pgp substrate activity, the only bronchodilator listed was epinephrine, which was reported not 
to be a substrate for the efflux pump transporter.  It may well be that due to the low levels of 
Pgp found within the lung, the necessity for circumvention of this transporter is unwarranted. 
The physiological relevance of the relatively high concentrations of compound needed to 
produce an inhibition of Pgp-mediated efflux needs to be explored further.   
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FIGURE LEGENDS 
Figure 1. (a) Structure of progesterone showing the position of 11-, 17- and 21-OH substitution.  (b) 
Relative transport efficiency of progesterone and some of its substituted analogs by Pgp (Gruol and 
Bourgeois, 1997). 
 
Figure 2.  (a) Structure and (b) chemical modification of dexamethasone and inhalation steroids tested.  
Known Pgp substrates (*) are marked as indicated. 
 
Figure 3.  Structure of β−ligands tested.  Known Pgp substrates (*) and Pgp modulators (¶) are 
marked as indicated. 
 
Figure 4.  Effect of 100 µM steroids on Rh123 accumulation (2 hours) in Calu-3 cells.  Numbers in bold 
correspond to the ranking system shown in Table 1. A log P or log Kow value for flunisolide (rank #7) 
could not be obtained. 
 
Figure 5. Dose – response of nadolol (N) and metoprolol (M) on Rh123 accumulation (2 hours) in Calu-3 
cells.  β-ligands were studied at 1, 10, 100, 500 and 1000 µM, and 5 µM CsA was used as the positive 
control. (* p < 0.05 compared to control)  
 
Figure 6.  Effect of 100 µM β-ligands on Rh123 accumulation (2 hours) in Calu-3 cells. Numbers in bold 
correspond to the ranking system shown in Table 2. 
 
 
 
Table 1.  Effect of progesterone, progesterone analogs, dexamethasone and inhalation steroids on 
Rh123 accumulation in Calu-3 cells.  Steroids are shown in decreasing estimated log P octanol/aqueous (log 
Kow) values.  The ranking system indicates the relative effect of each steroid, with 1 being the most 
potent, and 16 being the least effective.  Available measured log P octanol/aqueous values (log P) for Rh123, 
CsA and some steroids are indicated for comparison. (n.a. = data not available). 
 
 
 
 
Steroid   log P  log Kow Rank # 
 
progesterone  3.26#  3.67  1 
testosterone  3.31**  3.27  6 
17α, 21-OH  2.04#  3.15  9 
21-OH   2.70#  3.12  3 
17α-OH  2.74#  3.08  12 
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* Tayar et al. (1993)    ** Johnson et al. (1995)  
 # Ponec et al. (1986)    ¶ Lampidis et al. (1989) 
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Table 2.  Effect of β-ligands on Rh123 accumulation in Calu-3 cells.  β-ligands are shown in decreasing 
measured log Poctanol/aqueous (log P) values.  The ranking system indicates the relative effect of each β-
ligand, with 1 being the most potent, and 7 being the least effective.  Log P values and ranking for Rh123 
and CsA are included for comparison.   
 
 
 
 
 
 
 
 
 
 
 
*Boehringer Ingelheim, Inc.   # Leo et al. (1971) 
aLampidis et al. (1989)   ¶Taylor et al. (1985) 
^Terao et al. (1996)     @Mathias et al. (1996) 
 bTayar et al. (1993)    %Yang et al. (2000).
β-ligand   log P  Rank # 
 
propranolol   3.21%  1 
CsA    2.92b  -- 
timolol    1.91^  3 
metoprolol   1.88@  2 
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Figure 3.   
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Figure 4. 
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Figure 5. 
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Figure 6.   
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